You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

Mechanism of Bushen Jianpi decoction in preventing and treating osteoporosis caused by aromatase inhibitors in breast cancer treatment

Article type: Research Article

Authors: Huang, Xu-Huia | Liang, Rong-Huab | Su, Leb | Guo, Weib | Wang, Chang-Juna; *

Affiliations: [a] Department of Traditional Chinese Medicine, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, Guangdong, China | [b] Guangzhou University of Chinese Medicine, Guangzhou 510403, Guangdong, China

Correspondence: [*] Corresponding author: Chang-Jun Wang, Department of Traditional Chinese Medicine, Guangdong General Hospital, Guangdong Academy of Medical Sciences, No. 106 of Zhongsaner Road, Yuexiu District, Guangzhou 510080, Guangdong, China. Tel.: +86 20 8382 7812; Fax: +86 20 8382 7812; E-mail:gzwchj@163.com

Keywords: Bushen Jianpi decoction, breast cancer, AI treatment, osteoporosis

DOI: 10.3233/CBM-160281

Journal: Cancer Biomarkers, vol. 18, no. 2, pp. 183-190, 2017

Published: 27 February 2017
Get PDF open access

Abstract

PURPOSE:

Research on the mechanism of Bushen Jianpi decoction (BJD) for preventing and treating osteoporosis caused by aromatase inhibitors (AI) during treatment for breast cancer resection.

METHODS:

An ovariectomized mouse model was established using random division into 6 groups: a sham ovariectomized group, a blank control group, a control group, an alendronate group, a BJD group, and a drug combination group. Mice breast cancer cell lines (4T1) were cultured and seeded into the armpits of 6 groups of BALB/c mice. The mouse breast cancer postoperative model was built when resecting the tumor after 3 weeks following seeding tumor. After 1 weeks, the 6 groups of mice were given different drugs. Then the following analyses were made: estradiol (E2) levels and alkaline phosphatase (ALP) levels in the serum; detection of in vitro bone density and calcium and bone phosphorus content; tumor pathology and immunohistochemistry detection.

RESULTS:

The results suggested that BJD decreased levels of ALP in ovariectomized mice, and there was a trend for improved bone loss. BJD strengthened the trend of alendronate to improve bone loss, improved bone density, bone calcium and phosphorous, and reduced ALP. BJD had a certain role on the promotion of the expression of estrogen receptors (ERs) in the relapse of the tumor tissue.

CONCLUSIONS:

Combined therapy with BJD and alendronate can act synergistically against osteoporosis, which was possibly related to a reduced bone conversion rate through inhibiting bone resorption. BJD may block the MAPK signal pathway in breast cancer cells, increasing the expression of ERs and making cancer cells sensitive to endocrine treatment.

References

[1] 

Zelnak AB, , O'Regan RM. Optimizing endocrine therapy for breast cancer [J]. J Natl Compr Canc Netw. (2015) ; 13: (8): e56-e64.

[2] 

Chumsri S. Clinical utilities of aromatase inhibitors in breast cancer [J].Int J Womens Health. (2015) ; 7: : 493-499.

[3] 

Van Asten K, , Neven P, , Lintermans A, et al. Aromatase inhibitors in the breast cancer clinic: focus on exemestane [J]. Endocr Relat Cancer. (2014) ; 21: (1): R31-R49.

[4] 

Gobbi S, , Rampa A, , Belluti F, et al. Nonsteroidal aromatase inhibitors for the treatment of breast cancer: an update [J]. Anticancer Agents Med Chem. (2014) ; 14: (1): 54-65.

[5] 

Gai Xiaodan. The clinical observation of bone mineral density and total alkaline phosphatase in long-term supplement estrogen women with ovaries removed. Chin J Clin Rehabil. (2003) ; 7: (5): 810.

[6] 

Du Yu, , Tan Xiangling. The study of the source of alkaline phosphatase in blood of rats with osteoporosis. Shandong Medi J. (2011) ; 51: (19): 8-9.

[7] 

Du Ying, , Xie Jie, , Wei Hewei, et al. The clinical study of Bushen Jianpi Huoxue decoction in the treatment of osteoporosis. Chin J Clin Rehabil. (2005) ; 9: (35): 108-110.

[8] 

Ren Lin, , Qi Xiaowei. Sagopilone inhibits bone metastases and bone destruction in breast cancer by inhibiting tumor cell growth and bone absorption. Chin J Breast Dis. (2009) ; 3: (5): 574-576.

[9] 

Szulc P, , Delmas PD. Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis [J]. Osteoporos Int. (2008) ; 19: (12): 1683-1704.

[10] 

Kurebayashi J. Current clinical trials of endocrine therapy for breast cancer [J]. Breast Cancer. (2007) ; 14: (2): 200-214.

[11] 

Legault C, , Maki PM, , Resnick SM, et al. Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene. J Clin Oncol. (2009) ; 27: : 5144-5152.

[12] 

Kudachadkar R, , O'Regan RM. Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer. CA Caneer J Clin. (2005) ; 55: (3): 145-163.

[13] 

Tan Xiaoning, , Zhou Zhi, , Xie Xiaolei. The role of estrogen receptor signaling pathways in the development and treatment of breast cancer. Chin Bull Life Sci. (2011) ; 23: (10): 969-974.

[14] 

Creighton CJ, , Hilger AM, , Murthy S, et al. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res. (2006) ; 66: (7): 3903-3911.

[15] 

Gee JM, , Harper ME, , Hutcheson IR, et al. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology. (2003) ; 144: (11): 5105-5117.

[16] 

Bayliss J, , Hilger A, , Vishnu P, et al. Reversal of the estrogen receptor negative phenotype in breast cancer and rest oration of anti-estrogen response. Lincancer Res. (2007) ; 13: (23): 7029-7036.

Show more